首页> 外文期刊>Anesthesia and Analgesia: Journal of the International Anesthesia Research Society >Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery
【24h】

Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery

机译:血管紧张素转换酶抑制剂与非心脏手术后的呼吸系统并发症或死亡率无关

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: General use of angiotensin-converting enzyme inhibitors (ACEIs) is associated with upper-airway complications such as cough, angioedema, and bronchospasm; furthermore, preoperative use is associated with increased morbidity or mortality. Our primary goal in this study was thus to evaluate the association of ACEI therapy with perioperative respiratory morbidity in adult noncardiac surgical patients. Our secondary goals were to evaluate the association between preoperative use of ACEI and 30-day mortality, as well as to a composite outcome of in-hospital morbidity and mortality in adult noncardiac surgical patients having general anesthesia. METHODS: We evaluated 79,228 patients (9905 ACEI users [13] and 66,620 [87%] non-ACEI users) who had noncardiac surgery at the Cleveland Clinic between 2005 and 2009. Propensity matching successfully paired 9028 ACEI users (91% of 9905 patients) with 9028 controls. Matched intraoperative ACEI users and non-ACEI users were compared on intraoperative and postoperative respiratory morbidity composites as well as individual complications, 30-day mortality, and a composite of in-hospital morbidity and mortality. RESULTS: The association between ACEI use and respiratory morbidity composites was not statistically significant intraoperatively (OR: 1.09 [97.5% CI: 0.91, 1.31], ACEI versus non-ACEI; P = 0.28) or postoperatively (OR: 0.97 [97.5% CI: 0.81, 1.16], ACEI versus non-ACEI; P = 0.69). Within the propensity-matched subset, ACEI usage was not associated with either 30-day mortality (OR: 0.93 [95% CI: 0.73, 1.19], ACEI versus non-ACEI; P = 0.56) or the composite of in-hospital morbidity and mortality (OR: 1.06 [95% CI: 0.97, 1.15], ACEI versus non-ACEI; P = 0.22). We also observed that the ACEI and the non-ACEI groups were descriptively similar (standardized differences <0.03) on multiple time periods of intraoperative hemodynamic characteristics, vasopressor use, and colloid and crystalloid infusions. CONCLUSIONS: We did not find any association between use of ACEIs and intraoperative or postoperative upper-airway complications. Furthermore, ACEI use was not associated with in-hospital complications or increased 30-day mortality.
机译:背景:血管紧张素转换酶抑制剂(ACEIs)的普遍使用与上呼吸道并发症如咳嗽,血管性水肿和支气管痉挛有关。此外,术前使用会增加发病率或死亡率。因此,本研究的主要目标是评估成人非心脏外科手术患者的ACEI治疗与围手术期呼吸系统疾病的关联。我们的次要目标是评估术前使用ACEI与30天死亡率之间的关联,以及成人全身麻醉的非心脏手术患者的院内发病率和死亡率的综合结果。方法:我们评估了2005年至2009年期间在克利夫兰诊所进行过非心脏手术的79,228名患者(9905名ACEI用户[13]和66,620名[87%]非ACEI用户)。倾向匹配成功地将9028名ACEI用户配对(9905名患者中的91%) )与9028控件。比较匹配的术中ACEI和非ACEI使用者的术中和术后呼吸系统发病率综合指数,个体并发症,30天死亡率以及院内发病率和死亡率综合指数。结果:ACEI的使用与呼吸系统疾病的发生率之间的相关性在术中(OR:1.09 [97.5%CI:0.91、1.31],ACEI与非ACEI; P = 0.28)或术后(OR:0.97 [97.5%CI] :0.81、1.16],ACEI与非ACEI; P = 0.69)。在倾向匹配的子集中,ACEI的使用与30天死亡率(OR:0.93 [95%CI:0.73,1.19],ACEI与非ACEI; P = 0.56)或住院期间的综合发病率无关。和死亡率(OR:1.06 [95%CI:0.97,1.15],ACEI与非ACEI对比; P = 0.22)。我们还观察到,ACEI组和非ACEI组在术中血流动力学特征,使用升压药以及胶体和晶体输注的多个时间段上在描述上相似(标准差<0.03)。结论:我们没有发现使用ACEIs与术中或术后上呼吸道并发症之间有任何关联。此外,ACEI的使用与院内并发症或30天死亡率的增加无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号